MD Anderson and Myriad Genetics Form Strategic Alliance to Evaluate Clinical Utility of Myriad’s Molecular Residual Disease Assay

MD Anderson and Myriad announced a five-year strategic collaboration to accelerate the clinical evaluation and development of Myriad’s molecular residual disease assay. 

Read More